Hypothesis: This study aimed to elucidate the role of glibenclamide in the prevention of diabetic nephropathy and to compare it with a reference drug captopril in rats. Materials and methods: There were two main groups of rats. Control group (I) was subdivided into four subgroups which received distilled water, vehicle of streptozotocin, glibenclamide or captopril. The streptozotocin-diabetic Group (II) was subdivided into three subgroups: untreated, glibenclamide or captopril treated. Measurement of arterial blood pressure, serum glucose and creatinine levels, 24 h urinary protein and albumin/creatinine ratio, kidney weight and its histological examination were done after 1, 2, 4, 8, 12 and 16 weeks of treatment. Results: In treated diabetic rats captopril reduced blood pressure significantly, while no significant change in the mean arterial blood pressure or blood glucose level was recorded with glibenclamide treatment. Glibenclamide and captopriltreated diabetic rats showed significant decrease in serum creatinine level, urine volume, urinary protein excretion, albumin:creatinine ratio and kidney:body weight ratio compared with the diabetic non-treated group. Histological examination of diabetic kidneys treated with either glibenclamide or captopril showed reduced glomerular hypertrophy, glomerulosclerosis, tubular degeneration and interstitial fibrosis compared with untreated diabetic rats. Conclusion: Glibenclamide attenuated some biochemical and histological changes produced by diabetic nephropathy, despite persistent hyperglycemia and hypertension.
Introduction
Although sulfonylureas have long been therapeutically utilized for their hypoglycemic properties in type II diabetic patients, there is a lack of clinical or experimental data that suggest that this class confers a benefit on the course of diabetic renal disease.
Diabetic nephropathy (DN) is a leading cause of kidney disease in patients and affects approximately 40% of type I and type II diabetic patients. Over the last 35 years, an increasing number of patients with type II diabetes mellitus have developed advanced renal disease, and they require dialysis. The explanation for the increase in the number of patients with type II diabetes mellitus in end-stage renal disease programs is not completely clear. The basis for the prevention of DN is the effective treatment of its known risk factors: hypertension, hyperglycemia, smoking, and dyslipidemia. These risk factors should be vigorously treated. 1 Kvetny et al. 2 found that the use of perindopril for 3 years in normotensive, normoalbuminuric type 1 diabetic patients delayed the increase in albuminuria. Similarly, Lindholm et al. 3 reported that in patients with type 2 diabetes, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers both diminish the risk for DN. Blockade of the renin-angiotensin system (RAS) was proved to delay or prevent the onset of microalbuminuria, and attenuate progression of DN even in advanced stages. 4 It is also evident that prolonged tight glycemic control slows down the progression of DN in type 2 diabetes. Sulfonylurea compounds were the first available oral antidiabetic agents, and they remain an important tool for optimal glycemic control. 5 Beesley et al. 6 demonstrated the presence of a functional rat mesangial K ATP containing unique receptors for sulfonylureas. However, little is known about their possible functional and metabolic effects, independently of the increased insulin secretion and decrease glycemia induced by these compounds.
Asano et al. 7 demonstrated specific binding of the sulfonylurea glibenclamide (Glib) to mesangial cell (MC) membranes and, following exposure to it, there is increased intracellular Ca 2+ concentration and intense MC contraction. On the other hand, Cortes et al. 8 reported that MCs treated with high concentrations of tolazamide increased glucose uptake, transforming growth factor (TGF)-β1 secretion, and matrix accumulation, suggesting that this drug could aggravate diabetic glomerulosclerosis.
Therefore, because the initial observations regarding the effect of sulfonylureas on DN were contradictory, the present study has been undertaken to examine the effect of glibenclamide treatment on the progression of renal biochemical and histological changes in streptozotocininduced diabetes mellitus in rats, to determine whether therapeutic intervention with glibenclamide would prevent the onset and progression of renal complications independent of its effect on blood glucose, and to compare the results with a standard group of drugs (angiotensin-converting enzyme inhibitors) used in treatment of DN.
Materials and methods

Materials
Experimental animals. Male adult albino rats weighting 250-275 g were used throughout the study. Rats were housed in wire-topped plastic cages, five animals per cage, and kept under standard laboratory conditions with controlled temperature, 12 h light/dark cycle and given free access to a standard diet of rodent chow (12-15 g/d) and water ad libitum. The temperature inside the chambers was 22°C (± 2) with relative humidity from 40-60%. They were left to acclimatize for 1 week before the experiment was started. Animal care was carried in accordance with institutional guidelines.
Test drugs. Streptozotocin (STZ) (Sigma-Aldrich, St. Louis, USA) was freshly prepared in citrate buffer; glibenclamide (Sigma-Aldrich, St. Louis, USA), provided as powder, was dissolved in water; and captopril (Sigma-Aldrich, St. Louis, USA), provided as powder, was dissolved in water.
Methods
Induction of diabetes mellitus. Diabetes was induced by an intraperitoneal injection of a single dose of STZ (60 mg/kg body weight) after 18 h fasting. 9 STZ was dissolved in 0.1 M citrate buffer (pH 4.5) immediately before use. 10 Tail blood samples were obtained 72 h after the injection, in order to measure blood glucose concentration by using glucometer (Smart-DC, Germany), to ensure the successful induction of diabetes in STZ-treated animals. Animals were classed as diabetic when glycemia exceed 11 mmol/l (1 mmol = 18 mg glucose). 11 Animals with blood glucose levels above 200 mg/dl were selected for study.
Animal grouping. The rats were divided into two main groups. Group [I] was subdivided into four subgroups (48 rats each). In subgroup (Ia), rats were given distilled water orally in the same timing that drugs were administered to the other groups, and served as control group. In subgroup (Ib), rats were injected intraperitoneally with equivalent volumes of 0.1 M citrate buffer, and served as vehicle control. In subgroup (Ic), rats were given glibenclamide in a dose of 0.04 mg/kg/day orally, 12 and subgroup (Id) rats were given captopril (17.5 mg/kg/day) and served as a standard. 13 Group [II] (STZ-induced diabetes mellitus) rats were rendered diabetic by single intraperitoneal injection of STZ in a dose of 60 mg/kg. 9 The diabetic rats were randomized into three subgroups (48 rats each). Subgroup (IIa) served as untreated diabetic rats. Subgroups (IIb and IIc) rats were treated with glibenclamide or capropril, respectively, at the same doses previously mentioned.
Data collection. Six rats were randomly selected from each subgroup after 1, 2, 4, 8, 12 and 16 weeks of treatment. The following parameters were measured: arterial blood pressure, serum glucose and creatinine levels. In order to determine urinary protein and albumin-to-creatinine ratio, 24 h urine was collected from individually caged rats. 14 After sacrifice, the kidney:body weight ratio was determined.
Measurement of blood pressure. Blood pressure was measured in conscious rats, the day before sacrifice, using a tail-cuff monitor (model 65-12 manual scanner; IITC Life Science, Woodland, CA, USA).
Urine collection. For analysis of urine, 24 h urine volume was measured. Urine was centrifuged and 1 ml was stored at -20°C until the time of biochemical analysis of urinary albumin excretion (UAE), urinary creatinine level and determination of albumin:creatinine ratio.
Blood sampling.
A fasting blood sample was withdrawn from the retro-orbital venous plexus before scarification at 10 am for estimation of blood glucose. Sera was separated and stored at -20°C until the time of biochemical analysis of serum glucose and creatinine levels.
Ratio of kidney weight relative to body weight (KW:BW). The average weight of the animals was recorded on the day of sacrifice. The weight of the right kidney was determined, and hypertrophy of the kidney was estimated by comparing the weight of the kidney to the body weight. 15 
Histological assessment of kidney injury
At the end of the experiment, right kidneys from each group were fixed in 10% neutral buffered formalin and processed for 5 μm paraffin sections for Hematoxylin and eosin (H&E) staining, Masson trichrome staining and periodic acid-Schiff (PAS) reaction. Morphometric measurements of stained sections were performed in an image analysis system (Leica Qwin Imaging System, Ltd., Cambridge, England). All quantification was blinded.
For PAS-stained sections, glomerular sclerosis was evaluated as incremental degrees of PAS-positive substances, disappearance of cell components, collapse of capillary lumina, and entrapment of amorphous hyaline material associated or not with adhesions to Bowman's capsule as indicators, and was classified according to the criteria of Romero et al. 16 At least 50 glomeruli were randomly chosen and evaluated per biopsy at a magnification of ×400 using Leica Qwin image analysis software. Sclerosis involving more than 80% of the glomerular tuft was considered global, and sclerosis involving less than 80% was considered segmental. Results are expressed as the percentage glomeruli examined showing segmental or global sclerosis.
The glomerular sclerosis index (GSI) 17 (mesangial expansion) 18 was analyzed using PAS-stained kidney sections. At least 50 randomly chosen glomeruli were selected at a magnification of ×400. Using Leica Qwin imaging system software, each glomerulus was traced inside the basement membrane of the Bowman's capsule. The sclerotic index was obtained by measuring the total area (μm 2 ) of each glomerulus and then measuring the area of the PASpositive magenta-stained regions within the glomerulus. The sclerotic index was calculated for each glomerulus by dividing the total PAS-positive area (μm 2 ) by the total area (μm 2 ) of the glomerulus multiplied by 100. A mean sclerotic index was calculated for each animal. 17 Severity of tubular degeneration and atrophy, as well as tubulointerstitial infiltration (hematoxylin and eosin staining) and interstitial fibrosis (trichrome staining), were evaluated individually, determining the percentage in the biopsy section and scored using the criteria of Romero et al. 16 The severity of the tissue damage consists of the following five grades (scores) based on the ratio of the lesion area to the total area of the renal tissue in the visual field as follows; 0: lesion area < 10%; 1: 10% < lesion area < 20%; 2: 20% > lesion area < 40%; 3: 40% > lesion area < 60%; 4: 60% < lesion area < 80%; 5: lesion area > 80%. The average score obtained in the sections of each biopsy (10-15 sections per biopsy) was used as the score of the biopsy.
Statistical analysis of the results
Data are presented as means ± standard deviations. Comparison of data between two groups was done using the independent t-test. The difference was considered statistically significant when p < 0.05. Pearson correlation was done between different parameters.
Results
Effect of glibenclamide and captopril treatment on mean arterial blood pressure
Glibenclamide-treated non-diabetic rats had no significant change in mean arterial blood pressure compared with controls during the course of treatment, whereas captopril significantly lowered the mean arterial blood pressure in non-diabetic rats compared with control rats. Diabetic rats had significantly elevated mean arterial blood pressure at 4, 8, 12, 16 weeks of the study period compared with control rats. The respective glibenclamide-treated diabetic group had no significant change in mean arterial blood pressure compared with diabetic rats, while diabetic rats treated with captopril had a significant decrease in mean arterial blood pressure at 4, 8, 12, 16 weeks compared with diabetic rats and the glibenclamide-treated diabetic group (Figure 1 ). Significance was considered at p < 0.05, * significant change compared with control; # significant change compared with diabetic group; § significant change between diabetic + captopril group and diabetic + glibenclamide group.
Effect of glibenclamide and captopril treatment on kidney weight relative to body weight
There was a significant increase (p < 0.05) in the kidney weight relative to body weight (KW:BW) ratio in the diabetic group compared with the control group. Treatment of diabetic rats with glibenclamide or captopril significantly decreased the KW:BW ratio compared with the diabetic group throughout the study period, as shown in Figure 2 . It is to be noted that the KW:BW ratio was significantly lower in captopril-treated diabetic rats at 8, 12, and 16 weeks compared with that in the glibenclamidetreated group. However, there was no significant change between captopril-treated diabetics and control rats at weeks 8, 12 and 16.
Effect of glibenclamide or captopril treatment on blood glucose level
Glibenclamide significantly decreased blood glucose levels in non-diabetic rats starting from the first week, and levels were maintained lower than controls throughout the study period. However, there was no significant change between non-diabetics treated with captopril and controls, while there was a significant change between glibenclamide and captopril-treated non-diabetic rats. Administration of STZ caused a significant increase in the blood glucose level throughout the study period compared with the control group (p < 0.05). Diabetic animals treated with glibenclamide showed a significant reduction in blood glucose level compared with diabetic group throughout the study period (p < 0.05). Captopril-treated diabetic animals did not show significant reduction in blood glucose level compared with untreated diabetics; however, there was a significant change compared with glibenclamide-treated diabetic animals. All of these results are shown in Figure 3 .
Effect of glibenclamide or captopril treatment on serum creatinine level
Serum creatinine levels increased significantly in diabetic rats compared with the control group throughout the study period (p < 0.05). The serum creatinine level was significantly lower in the diabetic group receiving glibenclamide compared with their respective diabetic group. Moreover, there was a significant difference between the glibenclamide-treated diabetic and captopril-treated diabetic group at all time points considered throughout the study (p > 0.05). Captopril-treated diabetic animals showed a significantly lower serum creatinine level compared with that of the glibenclamide group. However, serum creatinine levels in both groups did not reach the control values ( Figure 4 ).
Effect of glibenclamide or captopril treatment on urine volume (ml/24 hours)
There was a significant increase in 24 h urine volume in the diabetic group compared with the control group throughout the study period. Although urine volumes in the glibenclamide treatment diabetic group tended to be lower than in the diabetic group, they were still significantly higher than those of the controls (p < 0.05). Captopril significantly reduced urine output compared with the diabetic group throughout the study period. There was no significant difference between glibenclamide or captopril-treated diabetic animals ( Figure 5 ). 
Effect of glibenclamide or captopril treatment on urinary protein excretion (mg/24 h)
Urinary protein excretion increased during the study in diabetic untreated rats (p < 0.05). Urinary protein excretion in glibenclamide-treated diabetic animals was significantly lower than in diabetic rats despite persistent elevated blood glucose level and despite elevated mean arterial blood pressure. However, urinary protein excretion in the glibenclamide-treated diabetic group was still significantly higher than that of the controls. Urinary protein excretion in captopril-treated diabetic rats decreased significantly compared with the diabetic group; moreover, it showed a non-significant difference compared with control rats (Figure 6 ).
Effect of glibenclamide or captopril treatment on urinary albumin:creatinine ratio of diabetic rats
Diabetic rats showed a significant increase in albumin: creatinine ratio (ACR). Administration of glibenclamide in STZ-treated rats showed a significant decrease of ACR compared with the diabetic group. However, the ACR was still significantly higher than the control group (p < 0.05). Captopril-treated diabetic animals showed a significant decrease in ACR compared with their respective diabetic group, and there was no significant difference compared with the control group (Figure 7 ).
There was no significant difference between control untreated and citrate buffer control for all parameters.
Histological results
Group (I) Subgroup Ia. In the control untreated rats, the kidney had normal histological architecture. Minimal amounts of collagen fibers were found, and were confined to the Bowman's capsule, around the tubules and basal laminae of glomerular capillaries. PAS-positive materials were observed in the basement membrane of renal tubules, as well as the brush border of the proximal convoluted tubules. Also, intraglomerular PAS-positive material was noted ( Figure 8 ).
Subgroup Ib, Ic and Id. The renal architecture in citrate buffer, glibenclamide and captopril-treated rats showed a nearly normal pattern. The PAS-positive materials were also indistinguishable from normal.
Group II (diabetic)
Subgroup IIa. No uniform pattern was found in the glomeruli, which appeared to be expanded and sometimes collapsed. Glomerular capillary loops were frequently dilated and congested. Confined areas showed variable grades of degeneration of glomeruli and tubules among apparently normal ones. This degeneration varied from vacuolization of epithelial cells lining both renal convoluted tubules up to complete destruction of these cells. The degenerated tubules were surrounded by minimal mononuclear cellular infiltration. Areas of extravasated blood cells were demonstrated in the interstitial tissue. Homogenous eosinophilic casts were seen in some tubules (Figures 9 and 10) .
However, Masson trichrome staining showed increased intraglomerular connective tissue and deposition of collagen fibers in focal cortical and medullary areas, being both perivascular and interstitial ( Figure 10 ). There was an intense increment in intraglomerular PASpositive material associated with the collapse of capillary lumens in some glomeruli. On the other hand, some proximal convoluted tubules showed a weak reaction in their brush border. Focal areas of interstitial tissue revealed a strong reaction ( Figure 11 ).
Subgroup IIb and IIc. Examination of kidney sections from glibenclamide and captopril-treated diabetic rats showed that the majority of the glomeruli and tubules were normal. There was no detectable abnormal connective tissue proliferation in the renal cortex. However, patchy interstitial fibrosis around collecting tubules was apparent in glibenclamide-treated rats. Cortical and medullary PAS reactions were apparently as normal as the control group (Figures 12  and 13 ).
Quantitative morphometric results
In group IIa (untreated diabetic), 34.8% of the area of the glomerular tuft was segmentally sclerosed and 31.0% was globally sclerosed. Administration of glibenclamide (Group IIb) and captopril (Group IIc) decreased significantly the glomerulosclerosis, especially the global sclerosis, compared with the untreated diabetic (Group IIa). Their global sclerosis was 2.5 and 5.0%, respectively ( Table 1) .
The Glomerular Sclerotic Index (GSI) increased in group IIa (diabetic animals). This was significantly different from treated groups IIb and IIc and control group Ia. The GSI of glomeruli from groups IIb and IIc (glibenclamide and captopril-treated diabetic rats) decreased significantly compared with non-treated diabetic rats, while there was no significant difference compared with control group Ia (Table 1) .
For renal tubules and interstitium, tubular degeneration and atrophy, interstitial cell infiltration and interstitial fibrosis were observed at a mean score of 3.2, 1.3 and 2.8, respectively, in the untreated diabetic group. Regarding these lesions, captopril (group IIc) significantly reduced the mean score, while the extent of these reductions was very similar to that in the glibenclamide-treated group IIb (Table 1) .
Meanwhile, there was no significant difference in the statistical analysis of the image analyzer data between both groups; IIb and IIc and the control group Ia. 
Discussion
The present study examined the effect of glibenclamide treatment on the progression of renal biochemical and histological changes in diabetic rats. It was designed to determine whether therapeutic intervention with these agents would prevent the onset and progression of renal complications or not compared with a reference drug, captopril, in the prevention of DN.
The STZ-diabetic animals represent a good experimental diabetic state with residual or remnant insulin production by pancreatic β-cells. Further, STZ-induced diabetes in rodents results in development of nephropathy, similar to early stage clinical nephropathy. Therefore, this animal model was selected for the study. 19 Our data revealed that 2 weeks after induction of diabetes mellitus, rats exhibited an increase in kidney weight relative to body weight, which accounts for early evidence of DN as reported by Mogensen et al. 20 The increase in rat kidney weight could be due to sustained hyperglycemia, either through direct toxicity to cells 21 or indirectly mediated through activation of protein kinase C (PKC)/mitogen-activated protein kinase (MAPK), 22 polyol pathway, 23 advanced glycation end products (AGE), 24 and oxidative stress. 25 Data from the present work demonstrated that treatment with glibenclamide produced a significant reduction in rat kidney weights and in kidney weight relative to body weight compared with the diabetic rats. This finding could be explained by Biederman et al., 26 who postulated that upregulation of mesangial α-endosulfine in the hyperglycemic milieu of insulin-deficient diabetes may retard glomerular extracellular matrix formation and mesangial expansion, hence prevent renal hypertrophy. Captopril, through blockade of the RAS, was proved to attenuate progression of DN. 4 There was no significant difference between diabetic rats receiving glibenclamide and the renoprotective comparator captopril as regards kidney hypertrophy. On the contrary, Katoh et al. 27 demonstrated that captopril failed to inhibit renal hypertrophy and elevation of creatinine clearance.
It is known that diabetic patients may develop variable degrees of glomerular sclerosis and tubulointerstitial fibrosis. 28 However, structural glomerular changes such as glomerular hypertrophy may be difficult to note unless careful measurements are made. 29 Nakagawa et al. 30 reported that glomerular hypertrophy was quantified as the glomerular tuft cross-sectional area.
Glomerular sclerosis was defined as an increment in intra-glomerular PAS-positive material associated with collapse of capillary lumens and amorphous hyaline material with or without adhesions to the Bowman's capsule. 18 Consistent with the results of Biederman et al., 26 the morphometric measurements in the present study showed glomerular hypertrophy, mesangial expansion and focal interstitial fibrosis in the case of diabetic non-treated animals as GSI was increased in comparison with the control animals. Meanwhile, the degree of glomerular hypertrophy and mesangial expansion for the diabetic treated animals was less than that seen in diabetic rats.
Giannico et al. 31 suggested that glibenclamide might directly attenuate diabetic glomerular disease, possibly by inhibiting plasminogen activator inhibitor-1 (PAI-1) expression. Excess glomerular PAI-1 allows the accumulation of extracellular matrix, leading to glomerulosclerosis.
These results have therapeutic implications for DN as well as for proliferative mesangial diseases of the kidney.
In the present work, a significant increase in the mean arterial blood pressure was observed in the diabetic nontreated rats. These findings are consistent with the observations of Stefan et al., 32 who found that mean arterial blood pressure was markedly increased in diabetics; on the other hand, the present results revealed that treatment with glibenclamide produced a non-significant reduction in elevated mean arterial blood pressure throughout the study period, unlike the data of Moreau et al., 33 who reported that the glibenclamide-induced blockade of vascular potassium channels caused a vasoconstriction in the systemic and splanchnic vascular beds and hence an increase in blood pressure. Williams et al. 34 reported that night-time systolic blood pressures were significantly higher during glibenclamide treatment than they were with placebo. Kulkarni et al. 35 reported that glibenclamide significantly prevented alloxan-induced hyperglycemia and hypoinsulinemia, but it failed to alter hypertension. In contrast to the present data were the data of Yosefy et al., 13 that glibenclamide worsened blood pressure control possibly by activation of the sympathetic system. On the other hand, Kamata et al. 36 reported that glibenclamide suppressed sodiuminduced hypertension through sodium excretion from the kidney resulting from accelerated secretion of urinary kallikrein.
Administration of captopril to diabetic rats significantly decreased mean arterial blood pressure at 4 weeks and prevented renal hypertrophy. Mogensen 37 reported that the renoprotective effect of captopril is independent of blood pressure reduction, while in the present study glibenclamide protected against renal hypertrophy without affecting mean arterial blood pressure. This means that the renoprotective effect of glibenclamide is not in part due to its effect on blood pressure. Captopril significantly reduced mean arterial blood pressure in normotensive dogs via a nitric oxide-independent mechanism, and did not affect postprandial glucose level in normoglycemic dogs. 38 Captopril significantly reduced blood pressure of diabetic mice at 28 days after the start of drug treatment. 27 The results of the present work showed that administration of glibenclamide following induction of diabetes decreased blood glucose levels in STZ-treated rats, while blood glucose in the captopril-treated diabetic did not show significant decrease compared with the diabetic group. Sulfonylurea improves peripheral glucose uptake and decreases endogenous glucose production independent of its insulin secretagogue action. 39 The decrease in glucose level may also be due to an increased sensitivity of peripheral tissues to released insulin and to insulin-like extrapancreatic effects; moreover, it could be due to an intensification of the transmembrane transport of glucose and an increase in glycolysis activity. 40 The present data demonstrate that diabetes mellitus produced a significant increase in serum creatinine compared with the control group, and showed that serum creatinine levels were significantly lower in the diabetic group receiving glibenclamide or captopril compared with their respective diabetic group. Induction of diabetes produced a significant increase in the 24 h urine volume, urinary protein excretion and urinary ACR compared with control rats. However, glibenclamide or captopril significantly decreased urine volume compared with the diabetic group. In addition, it decreased significantly both proteinuria and urinary ACR. Captopril-treated rats did not show significant changes relative to controls.
Diabetic rats in the present study experienced proteinuria and microalbuminuria. Microalbuminuria is an established marker of diabetic nephropathy. 41 However, these markers decreased following treatment with either glibenclamide or captopril. This could be explained as follows. The predominant action of angiotensin II is confined to the efferent arteriole, thereby inducing a rise in glomerular capillary hydraulic pressure. Conversely, angiotensin-converting enzyme inhibition diminishes glomerular capillary pressure in animals, and probably also in man. As albuminuria is dependent on glomerular hydraulic pressure, subsequently captopril reduced albuminuria. 42 The major source of oxidative stress in diabetes is reactive oxygen species (ROS) derived from the superoxide anion that is produced by nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase. Because angiotensin II stimulates NAD(P)H oxidase expression and activation in vasculature and in the kidney, angiotensin-converting enzyme inhibitor can effectively suppress NAD(P)H oxidase and decrease microalbuminuria in diabetic rats. 43 In insulin-deficient diabetic rats, sulfonylureas significantly reduced the enhanced albumin excretion, because glibenclamide may improve the afferent arteriolar dilatation, thereby reducing glomerular hyperfiltration. 26 Recently, Tanwar et al. 44 reported that glibenclamide as a reference anti-hyperglycemic compound attenuated renal dysfunction by significantly decreasing urine volume and albuminuria in STZ-induced diabetic rats. In contrast, Nakamura et al. 45 reported that glibenclamide did not reduce urinary albumin excretion in non-insulin-dependent diabetes mellitus patients with microalbuminuria.
In the present study, the kidneys of diabetic non-treated rats revealed focal tubular degeneration at multiple points along the nephron, with large skip areas in between, often accompanied by the presence of casts in tubular lumina. The casts were eosinophilic and hyaline. Furthermore, interstitial fibrosis and mononuclear infiltrating cells around dilated blood vessels and degenerated tubules were demonstrated. However, treatment with glibenclamide and captopril mostly preserved the morphology of the glomeruli and tubules. Zafiriou et al. 46 settled the hypothesis that elevated low-density lipoprotein (LDL) levels may play a role in the development of tubular pathology. Concurrent exposure to albumin and LDL might result in reduced albumin uptake and hence tubular degeneration. So, the reduction in proteinuria following treatment with glibenclamide and captopril would reduce tubular degeneration.
It could be concluded that glibenclamide attenuated some biochemical and histological changes produced by DN. It resulted in a reduction in renal changes that accompany diabetes, despite persistent hyperglycemia and hypertension. It could be suggested that the protective effect of glibenclamide in DN is independent of its effect on blood glucose level. Further studies are needed to investigate whether the protective effect of glibenclamide could be due to its direct effect on sulfonylurea receptors (SUR2B) in the kidney. Based on the obtained results, a potential new therapeutic field is opened for the study of protective tools in DN; one could recommend that human clinical trials are necessary to prove this protective effect. 
